We recently generated a novel human anti-PD-L1 mAb, called PD-L1_1, which was found to have the capacity to interfere in the PD-L1/PD-1 interaction, to strongly activate T-cell proliferation and to induce cytokine secretion more efficiently than the clinically validated antibodies Nivolumab an...
Programmed death 1 expression in cancer and infection: tissue versus periphery PD-1:PD-L1 blockade as host-directed therapy Anti-PD-1:PD-L1/2 therapy: improved efficacy with acceptable toxicity Anti-PD-1 versus anti-PD-L1/2 therapy and opportunities for combination with other immunotherapies Conc...
An example of this is the success of the combination of Vγ9Vδ2 T cells and therapeutic PD-1 monoclonal antibodies (mAbs) that enhanced the cytotoxicity of Vγ9Vδ2 T cells.26,27,28 In another preclinical experiment of PC-3 prostate tumors treated with Vγ9Vδ2 T cells, anti-PD-1 ...
Our treatment-naïve BCC patient, who expressed PD-L1 on < 1% of both tumor cells and TILs, did not respond to anti-PD-1 im- munotherapy. These conflicting results most likely reflect the different mAbs used to detect PD-L1 expression and the PD-L1 cut-off adopted, and/or the ...
ANTI-PD-1抗体及其用途.pdf,本公开内容涉及一种结合至程序性细胞死亡‑1(PD‑1)蛋白质的蛋白质结合剂、抗体、其抗原结合片段。本公开内容提供额外对本公开内容的蛋白质结合剂、抗体、其抗原结合片段进行加密的多核苷酸序列、包含其的载体、宿主细胞。另外,本公开内容提
Although anti-PD-1 mAbs treatments for lung cancers have had some positive results there has been considerable serious concerns raised with deleterious side effects and increased risk of mortality in some elderly patients [86–89]. Equally important, continuous treatment of PD-1 mAbs, potentiate a...
Anti-PD-1 favors chromatin opening in loci linked to T-cell activation, memory and pluripotency, but in the absence of Suv39h1, cells acquire accessibility in cytolytic effector loci. Overall, Suv39h1 inhibition enhances anti-tumor immune responses, alone or combined with anti-PD-1, suggesting...
Provided are an anti-VEGFA-anti-PD-1 bispecific antibody and a use thereof. Specifically, the anti-VEGFA-anti-PD-1 bispecific antibody comprises: a PD-1-targeted first protein funct
The present invention relates to antibodies and antigen-binding fragments thereof that bind to PD-1, and to methods of using such antibodies and antigen-binding fragments. For examp
“PD1”, “PD-1”, “PDCD1”, “PD-1 antigen”, “human PD-1”, “hPD-1” and “hPD1” are used interchangeably and refer to the Programmed Death-1 receptor, also known as CD279, and include variants and isoforms of human PD-1, and analogs having at least one common epitope wit...